AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Lifecare ASA

Regulatory Filings Jul 2, 2024

3654_rns_2024-07-02_c8d6f73b-ab28-40bc-a97b-7a5741ed00fb.pdf

Regulatory Filings

Open in Viewer

Opens in native device viewer

LIFE: CLEANROOM ARRIVED IN HAMBURG

Bergen, Norway, July 2, 2024: Lifecare ASA (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the cleanroom for automated production has arrived in Hamburg.

Reference is made to Lifecare's stock exchange announcement March 5, 2024, regarding placing a purchase order for cleanroom in connection with the company's automated production. Due to disturbances to the sea trade routes through the middle east and Africa, the shipment of the cleanroom has been delayed. The shipment is now confirmed as arrived in Hamburg, Germany and is pending custom clearance.

  • Lifecare is subsequently left with no other choice than rescheduling the installation of cleanroom to late July and early August, and is aiming to launch the Pilot Production Site within the new timeframe of Q3 2024, says CEO Joacim Holter at Lifecare.

The importance of cleanroom

Cleanrooms are always required where the airborne particles are likely to contaminate the final product. Lifecare's cleanroom, which holds an ISO 7 standard, will ensure that the airborne particles are maintained at a very low concentration to not interfere with crucial functions of sensor components during sensor manufacturing. The sensor components consist of micro and nano technologies sensitive to particles. The airborne particles could potentially impact the functionality of the sensor by blocking the nano filtration layers and subsequent flow of the substances in and out of sensor cavities.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

Talk to a Data Expert

Have a question? We'll get back to you promptly.